Table 2. Treatment-related adverse events at least possibly related to PD-1/PD-L1 immunotherapy.
| Event | Grade 1, n (%) | Grade 2, n (%) | Grade 3, n (%) | Total, n (%) |
|---|---|---|---|---|
| Anya | 22 (35.5) | 16 (25.9) | 4 (6.5) | 42 (67.7) |
| Reactive capillary hemangiomas | 9 (14.5) | 6 (9.7) | 0 | 15 (24.2) |
| Rash | 8 (12.9) | 6 (9.7) | 0 | 14 (22.6) |
| Fatigue | 9 (14.5) | 3 (4.8) | 1 (1.6) | 13 (21.0) |
| Fever | 6 (9.7) | 2 (3.2) | 0 | 8 (12.9) |
| Hypothyroidism | 5 (8.1) | 2 (3.2) | 0 | 7 (11.3) |
| ALT increase | 4 (6.5) | 1 (1.6) | 1 (1.6) | 6 (9.7) |
| AST increase | 4 (6.5) | 1 (1.6) | 1 (1.6) | 6 (9.7) |
| Pruritus | 4 (6.5) | 0 | 0 | 4 (6.5) |
| Diarrhea | 3 (4.8) | 0 | 0 | 3 (4.8) |
| Hypocortisolism | 2 (3.2) | 1 (1.6) | 0 | 3 (4.8) |
| Dizziness | 3 (4.8) | 0 | 0 | 3 (4.8) |
| Anorexia | 3 (4.8) | 0 | 0 | 3 (4.8) |
| Stomatitis | 2 (3.2) | 0 | 0 | 2 (3.2) |
| Hyperthyroidism | 2 (3.2) | 0 | 0 | 2 (3.2) |
| Peripheral neuropathy | 0 | 0 | 1 (1.6) | 1 (1.6) |
| Myasthenia Gravis | 0 | 0 | 1 (1.6) | 1 (1.6) |
| Anemia | 1 (1.6) | 0 | 0 | 1 (1.6) |
| Nausea | 1 (1.6) | 0 | 0 | 1 (1.6) |
| Constipation | 1 (1.6) | 0 | 0 | 1 (1.6) |
| Total bilirubin increase | 1 (1.6) | 0 | 0 | 1 (1.6) |
| Unconjugated bilirubin increase | 1 (1.6) | 0 | 0 | 1 (1.6) |
| Myalgia | 1 (1.6) | 0 | 0 | 1 (1.6) |
| Nephritis | 0 | 1 (1.6) | 0 | 1 (1.6) |
a, worst per patient. ALT, alanine aminotransferase; AST, aspartate aminotransferase; PD-1, programmed cell death protein-1; PD-L1, programmed cell death-ligand 1.